MiMedx Group, Inc (MDXG): Price and Financial Metrics

MiMedx Group, Inc (MDXG): $3.54

0.10 (+2.91%)

POWR Rating

Component Grades














  • Sentiment is the dimension where MDXG ranks best; there it ranks ahead of 96.69% of US stocks.
  • The strongest trend for MDXG is in Growth, which has been heading up over the past 179 days.
  • MDXG ranks lowest in Momentum; there it ranks in the 13th percentile.

MDXG Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MDXG is -14.89 -- better than merely 1.28% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -11.74 for MIMEDX GROUP INC; that's greater than it is for only 1.81% of US stocks.
  • Over the past twelve months, MDXG has reported earnings growth of 181.89%, putting it ahead of 91.82% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MIMEDX GROUP INC are SIEN, DTSS, TZOO, ESTA, and MKTW.
  • Visit MDXG's SEC page to see the company's official filings. To visit the company's web site, go to www.mimedx.com.

MDXG Valuation Summary

  • MDXG's EV/EBIT ratio is -12.8; this is 295.42% lower than that of the median Healthcare stock.
  • Over the past 184 months, MDXG's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MDXG.

Stock Date P/S P/B P/E EV/EBIT
MDXG 2023-03-17 1.6 -23.4 -11.4 -12.8
MDXG 2023-03-16 1.6 -23.5 -11.5 -12.9
MDXG 2023-03-15 1.5 -22.6 -11.0 -12.3
MDXG 2023-03-14 1.6 -23.8 -11.6 -13.0
MDXG 2023-03-13 1.6 -24.5 -12.0 -13.4
MDXG 2023-03-10 1.6 -24.4 -11.9 -13.4

MDXG Growth Metrics

    The 3 year price growth rate now stands at -24.26%.
  • The 2 year price growth rate now stands at -24.26%.
  • The year over year net cashflow from operations growth rate now stands at 77.59%.
MDXG's revenue has moved up $19,607,000 over the prior 24 months.

The table below shows MDXG's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 267.841 -17.893 -36.777
2022-09-30 260.875 -15.501 -34.049
2022-06-30 256.26 -10.13 -27.866
2022-03-31 257.542 -5.526 -18.646
2021-12-31 258.615 -1.982 -16.421
2021-09-30 259.754 -9.017 -35.098

MDXG's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MDXG has a Quality Grade of C, ranking ahead of 64.26% of graded US stocks.
  • MDXG's asset turnover comes in at 1.366 -- ranking 8th of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows MDXG's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 1.366 0.833 -0.426
2021-06-30 1.316 0.833 -1.110
2021-03-31 1.302 0.842 -1.153
2020-12-31 1.369 0.842 -1.200
2017-09-30 1.597 0.881 0.532
2017-06-30 1.485 0.878 0.420

MDXG Price Target

For more insight on analysts targets of MDXG, see our MDXG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.17 Average Broker Recommendation 1.5 (Moderate Buy)

MDXG Stock Price Chart Interactive Chart >

Price chart for MDXG

MDXG Price/Volume Stats

Current price $3.54 52-week high $5.05
Prev. close $3.44 52-week low $2.43
Day low $3.46 Volume 621,600
Day high $3.61 Avg. volume 580,493
50-day MA $4.02 Dividend yield N/A
200-day MA $3.48 Market Cap 403.85M

MiMedx Group, Inc (MDXG) Company Bio

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue.

MDXG Latest News Stream

Event/Time News Detail
Loading, please wait...

MDXG Latest Social Stream

Loading social stream, please wait...

View Full MDXG Social Stream

Latest MDXG News From Around the Web

Below are the latest news stories about MIMEDX GROUP INC that investors may wish to consider to help them evaluate MDXG as an investment opportunity.

MIMEDX Announces Chief Financial Officer Transition

Executive Search UnderwayMARIETTA, Ga., March 23, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company has initiated a search for its next Chief Financial Officer and Mr. Carlson will be assisting MIMEDX throughout this process to ensure a smooth transition. “In the three years P

Yahoo | March 23, 2023

MIMEDX Comments on Recent Data Brief Published by Office of Inspector General

Company applauds the Office of Inspector General’s (“OIG”) recommendation for the Centers for Medicare and Medicaid Services (“CMS”) to quickly address issues associated with Average Sales Price (“ASP”) reporting requirements for skin substitute productsMARIETTA, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today applauded the recent report published by OIG entitled, “Some Skin Substitute Manuf

Yahoo | March 16, 2023

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2022 Earnings Call Transcript

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2022 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. […]

Yahoo | March 3, 2023

MiMedx Group Full Year 2022 Earnings: In Line With Expectations

MiMedx Group ( NASDAQ:MDXG ) Full Year 2022 Results Key Financial Results Revenue: US$267.8m (up 3.6% from FY 2021...

Yahoo | March 3, 2023

Institutional investors own a significant stake of 38% in MiMedx Group, Inc. (NASDAQ:MDXG)

Key Insights Institutions' substantial holdings in MiMedx Group implies that they have significant influence over the...

Yahoo | March 1, 2023

Read More 'MDXG' Stories Here

MDXG Price Returns

1-mo -22.03%
3-mo 27.80%
6-mo 29.20%
1-year -25.00%
3-year 123.34%
5-year 5.83%
YTD 27.34%
2022 -53.97%
2021 33.04%
2020 19.79%
2019 323.46%
2018 -85.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.93 seconds.